Outcomes38

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

21 to 38 of 38

Download this page as JSON

Type	Outcome	Time frame	Population	Units	Measured as
SECONDARY	ONTARGET. New Onset of Atrial Fibrillation	56 months	Only patients of the ONTARGET trial treated with Telmisartan 80mg/ramipril 10mg or Telmisartan 80mg/Ramipril 10mg placebo or Ramipril 10mg/ telmisartan 80mg placebo daily for 56 months without atrial fibrillation at baseline.	participants	NUMBER
SECONDARY	TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke	56 months	FAS of the TRANSCEND trial	participants	NUMBER
PRIMARY	TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. Cardiovascular Death	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. Non-fatal Myocardial Infarction	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. Non-fatal Stroke	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. Hospitalization for Congestive Heart Failure	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. Doubling of Serum Creatinine	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. Progression to ESRD	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. New Microalbuminuria	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. New Macroalbuminuria	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. Combined Endpoint of Doubling Serum Creatinine, Progression to ESRD, New Microalbuminuria or New Macroalbuminuria	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. New Onset of Atrial Fibrillation	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. Cognitive Decline	56 months	Only patients of the TRANSCEND trial treated with Telmisartan 80mg or telmisartan 80mg placebo daily for 56 months with Mini mental state evaluation (MMSE) at baseline.	participants	NUMBER
SECONDARY	TRANSCEND. Newly Diagnosed Diabetes	56 months	Only for patients of TRANSCEND trial treated with Telmisartan 80mg or Telmisartan 80mg placebo daily for 56 months without diabetes at baseline.	participants	NUMBER
SECONDARY	TRANSCEND. Cardiovascular Revascularization Procedure	56 months	FAS of the TRANSCEND trial	participants	NUMBER
SECONDARY	TRANSCEND. Newly Diagnosed Congestive Heart Failure	56 months	FAS of the TRANSCEND trial	participants	NUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00153101/outcomes?page=2

API reference For AI assistants

Outcomes38

Sources 3

Read this list from software.